Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
P4HA2 antisense RNA 1 (P4HA2-AS1) is a long non-coding RNA transcribed as the antisense complement of the protein-coding gene P4HA2. At present, there is virtually no empirical evidence supporting its function as a drug target, disease biomarker, or mediator of disease. Most references to P4HA2 in oncology, fibrosis, and other pathological states relate to the protein-coding enzyme prolyl 4-hydroxylase subunit alpha-2 (P4HA2), not this lncRNA. Therefore, this entry is not a canonical therapeutic target and should be distinguished from P4HA2. If your intent was to inquire about the protein-coding gene P4HA2 (prolyl 4-hydroxylase subunit alpha-2)—a validated target in oncology and tissue remodeling—please clarify, as its attributes differ significantly[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on P4HA2 antisense RNA 1 (non-protein coding) (P4HA2-AS1).